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Purpose: To report clinical, histopathological, and treatment features of small cell carcinoma of (SmccB) bladder 
during 7 years in a referral center. 
Methods: The clinical, histopathological features, treatment modalities, and outcome of all patients with bladder 
SmccB treated between 2009 and 2016 who were managed in Hasheminejad Kidney Center (HKC) were retro-
spectively collected.
Results: Thirteen patients were diagnosed and managed with SmccB. The average age of patients was 64.92 years. 
For each patient, 8 markers were used for IHC staining on average. Neuroendocrine markers such as CD 56, Neu-
ron Specific Enolase, Synaptophysin, and Chromogranin were found in a significant percentage of patients (69%, 
38%, 54%, and 31% respectively). Patients were managed with TURBT alone (N=3), chemotherapy after TURBT 
(N=4), chemotherapy plus radical surgery (N=4) and radical surgery alone (N=2). The best clinical result was seen 
in chemotherapy received patients with or without radical surgery. The mean(SE) of survival rate in patients who 
received only chemotherapy alone was 42.4 (10.0) months, while in those who were managed with chemotherapy 
plus radical surgery it was 47.7 (10.1) months.
Conclusion: In our center immunohistochemistry was needed for definitive diagnosis in 17/19 samples. Misdi-
agnosis happened in two samples without IHC request. We think that use of immunohistochemistry should be 
mandatory for diagnosis of SmccB to exclude misdiagnosis. Chemotherapy is the most important part of treatment 
and the addition of radical surgery can slightly improve patients’ survival.
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INTRODUCTION
Primary Small cell carcinoma of the bladder (SmccB) is a highly invasive and rare tumor of the urinary 
system(1). Although the lung is the most common organ 
involved by small cell carcinoma, this type of tumor can 
also affect many extra-pulmonary organs(1,2). As many 
as 2-9% of cases of small cell carcinoma (Smcc) are ex-
tra-pulmonary, and following gastrointestinal tract, the 
bladder is the third most common site of involvement(3).
SmccB accounts for 0.5 to 0.7% of all bladder tumors 
(4,5). Although this tumor is rare, it is not insignificant 
in any way(6). This tumor has been considered by many 
scholars due to its difficulties in diagnosis, aggressive 
behavior, poor prognosis, rapid progression, and sys-
temic nature(1). The rarity of SmccB has limited our 
knowledge of the biological progression of this malig-
nancy and thus prevented the ability to plan randomized 
prospective studies(1,7). In the literature, a few papers 
have been published on the optimal clinical guidelines 
for SmccB(6). There is still no therapeutic approach 
which is universally accepted and because of the rarity 
of the disease, the treatment modalities are not standard.
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The behavior of SmccB is far more invasive than that of 
urothelial cell carcinoma (UCC). Despite similar clini-
cal and demographic risk factors, and diagnostic meth-
ods, the prognosis of SmccB is much worse than UCC 
(7), and therefore, its definitive diagnosis is very impor-
tant. Pathologic diagnosis according to WHO criteria is 
performed through light microscopy, but some patholo-
gists recommend immunohistochemical (IHC) staining 
for diagnosis and some others consider it mandatory.
In this study, we present the clinical as well as histo-
pathological characteristics, therapeutic options, and 
outcomes of the SmccB patients managed in our center 
during a seven-year period, and emphasize the use of 
IHC staining for confirmation of pathologic diagnosis.
MATERIALS AND METHODS
From March 2009 until March 2016, 2763 patients 
with suspicious diagnosis of bladder tumors underwent 
transurethral resection of bladder tumor (TURB) in our 
center. A total of 301 cases later underwent radical cys-
tectomy with urinary diversion. Hospital files of all pa-
tients with a final diagnosis of SmccB were reviewed.
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Demographic characteristics, clinical symptoms, and 
the most common cause of referral were extracted and 
recorded. The results of imaging studies including size 
and location of the mass, the presence or absence of hy-
dronephrosis, local extension of tumor, and ultimately, 
lymph node involvement were recorded.
Serum hemoglobin and creatinine levels, preoperative 
urine cytology, therapeutic options including type of 
surgical procedure, chemotherapy regimen, and final 
pathological staging of tumor as well as multiple mark-
ers used in IHC staining of patients were recorded.
The patient’s latest health status was obtained via phone 
call (at the end of October 2016)
Data was entered into SPSS software ver.19. 
Kaplan-Meier curves were employed to display surviv-
al and comparison of survivals across treatment groups 
was performed by logrank test. Statistical significance 
was set a P-value less than 0.05. 
RESULTS
During this period, 13 patients with a mean age of 
64.92 years (range; 41-83) were diagnosed with Smc-
cB. Three patients were female and ten were male. The 
reasons for referral were gross hematuria (12/13), ure-
mia due to bilateral hydroureteronephrosis (6/13), low-
er abdominal pain due to large bladder mass (3/13), and 
flank pain (1/13).
The mean (range) of presentation hemoglobin (Hb) 
was 10.7 (7.7-14.8) mg/dL. Renal functional impair-
ment (Cr > 1.5 mg/dL) was observed in six patients. 
The mean (range) of presentation creatinine was 2.1 
(0.9-4.7) mg/dL. The findings of imaging modalities 
were large bladder mass, which had often a size greater 
than 5 cm. Unilateral (N=1) or bilateral hydronephrosis 
(N=6) was observed in seven patients. In all patients, 
urinary cytology was positive for the presence of malig-
nant cells. Demographic, clinical, and laboratory data 
on patients has been presented in Table 1.
All patients underwent TURBT. In 11 patients, histo-
logic examination on primary TURB specimen was not 
diagnostic and only after IHC staining SmccB diagno-
sis was confirmed. In two patients in whom IHC was 
not performed, the initial histologic report of TURBT 
specimen was high grade poorly differentiated urotheli-
al carcinoma (Figure 1). These two patients underwent 
radical cystectomy and the pathology report after radi-
cal cystectomy revealed SmccB of bladder. Details of 
pathological reports are presented in Table 2.
Treatment methods in our patients were TURBT alone 
(3/13), TURBT with chemotherapy (4/13), radical sur-
gery combined with chemotherapy (4/13), and radical 
surgery alone (2/13) (Figure 1). The chemotherapy reg-
imen included six courses of cisplatin and Gemcitabine.
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Table 1. Summary of demographic and clinical characteristics of 
13 patients.
Table 2. Pathologic and histologic details..
 Characteristics 
Gender; Male/Female   10/3
Age; mean, range   64.92 ( 41-83 ) years
Gross hematuria   12/13
Lower abdominal pain ( large pelvic mass ) 3/13
Uremia    6/13
Flank pain   1/13
Creatinine at diagnosis; mean, range  2.13 mg/dl ( 0.9 – 4.7 )
Hemoglobin at diagnosis; mean, range 10.7 mg/dl ( 7.7 – 14.8 )
Tumor size in imaging; mean, range  7.54 cm ( 2 – 12 )
Bilateral hydronephrosis  6/13
Unilateral hydronephrosis  1/13
Abbreviation: SmccB, small cell carcinoma of bladder
  Stage 
At least T2   7/13
T3a N ̶    1/13
T3a N+    1/13
T3b N+    1/13
T4a N+    3/13
Pure SmccB   10/13
SmccB + UCC   1/13
SmccB + UCC + CIS   2/13
Abbreviations: SmccB, small cell carcinoma of bladder; UCC, 
urothelial cell carcinoma; CIS, carcinoma insitu
Figure 1. Summary of Treatments and Survival.
Abbreviations: TURBT, transurethral resection of bladder tumor; CMT, chemotherapy; RC, radical cystectomy
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The reasons for the differences in the treatment mo-
dalities were clinical judgment, patient's health, serum 
creatinine, performance status as well as his/her desire. 
The summary of treatment and survival has been shown 
in Table 3 and Figures 2 through 5. The mean (stand-
ard error (SE)) of survival in patients who received and 
did not receive chemotherapy were 36.4 (8.5) vs. 6.5 
(1.0) months (P = .009; Figure 2) while the difference 
based on receiving surgery was not statistically signif-
icant (Figure 3). The mean (SE) survival of patients in 
clinical / pathological stages of T2, T3, and T4 inde-
pendently of their treatment strategy were 41.1 (11.1), 
25.1 (12.6), and 28.4 (11.6) months respectively (P = 
.73; Figure 4) The mean (SE) of survival in patients 
without any treatment, only surgery, only chemother-
apy, and chemotherapy with radical surgery were 4.9 
(1.2), 8.8 (0.6), 42.4 (10.0), and 47.7 (10.9) months re-
spectively (P = .001; Figure 5)
In macroscopic pathologic examination, all cases 
showed a large tumor, filling most of the bladder cavity. 
Gross areas of necrosis were also evident. In all cases, 
areas of invasion into muscularis propria were noted. 
Diagnosis of SmccB, however, was suggested in simple 
microscopic examination of tissues but for definitive di-
agnosis, IHC staining was recommended for 17 pathol-
ogy samples (11 TURBT and 6 radical surgery cases; 
Figure 6). As previously stated the pathology diagnosis 
in the only two samples which were reported without 
IHC staining was inaccurate (Figure 1).
IHC staining was performed with an average of eight 
markers(6–16) for each patient.
We used a panel of neuroendocrine markers as CD 56, 
Neuron Specific Enolase (NSE), Synaptophysin, and 
Chromogranin to confirm the diagnosis (Figure 6). At 
least two of these markers were positive in each patient 
(Table 4). We also performed a combination of IHC 
staining for CK 7, CK 20, P63, CD 45, PSA, CD 99, 
Desmin, and Myogenin to rule out urothelial carcino-
ma, lymphoma, prostatic adenocarcinoma, Ewing sar-
coma, and rhabdomyosarcoma.
DISCUSSION
Table 3. Summary of all patients’ data.
N Age Gender Serum Cr C stage* RC CMT P Stage Survival Follow up (months)
1 77 male 1.63 T2 ND D T2* Alive 54
2 41 male 3.3  D D T3b N+ Alive 52.8
3 75 female 1.0 T3 ND ND T2* Deceased 6.2
4 59 male 1.4  D D T4a N+ Alive 50.5
5 47 male 1.3 T2 ND D T2* Alive 40.7
6 75 male 4.7 T2 ND ND T2* Deceased 2.6
7 62 male 1.9 T4 N+ ND ND T2* Deceased 6
8 62 male 2.8  D D T4a N+ Alive 60.3
9 62 female 1.3  D D T3a N+ Deceased 10
10 61 female 2.2  D ND T4a N+ Deceased 8
11 66 male 4.1 T4 ND D T2* Deceased 7.6
12 74 male 1.2  D ND T3a N- Alive 9.6
13 83 male 0.9 T2 ND D T2* Alive 9.4
Abbreviations: RC, radical cystectomy; CMT, chemotherapy; p Stage, pathological stage; D, done; ND, not done; Cr, creatinine
T2*: least pathological stage because patient only underwent TURBT
C stage*: clinical stage according to imaging in patients only underwent TURBT
Figure 2.  Kaplan-Meier curves to compare survival across surviv-
al based on receiving chemotherapy (dotted line denoted patients 
who received chemotherapy and solid line indicates patients who 
did not receive chemotherapy)
Figure 3. Kaplan-Meier curves to compare survival across surviv-
al based on receiving surgery or not (dotted line denoted patients 
who received surgery and solid line indicates patients who did not 
receive surgery)
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The results of this study reveals that for definitive di-
agnosis of SmccB, IHC is necessary as in all properly 
diagnosed pathology specimens, IHC was performed 
and in 2 improperly diagnosed samples, IHC was not 
requested. Furthermore, chemotherapy seems to be 
the mainstay of treatment, however adding surgery to 
chemotherapy may increase patient survival; however 
this benefit was not statistically significant in our series.
Smcc is a rare tumor with a very aggressive behavior, 
and accounts for less than 1% of bladder malignancies 
(2,8). Despite the recognition of disease since 1981 by 
Cramer et al.(9), less than 1,000 cases of this disease 
have been reported so far, and most published studies 
are small case series(6). This type of bladder cancer has 
many challenging aspects especially in diagnosis and 
treatment methods.
The histological diagnosis of the disease is not so easy 
and evidence suggests that diagnostic errors in the 
bladder Smcc may occur frequently. A large study by 
Linder and his colleagues reclassified SmccB in 9% of 
the cases with inconsistency in previous histopatholog-
ical diagnosis(10). In another study by Kaushik et al., a 
review by a uropathologist, the rate of SmccB detection 
increased(11). Diagnosis of SmccB is based on the WHO 
criteria by light microscopic examination(12). On micro-
scopic examination, discrimination of SmccB from pul-
monary type is impossible(13). The tumor usually shows 
a patternless diffuse growth, composed of round small 
cells in nests or sheets with scant cytoplasm, hyper-
chromatic nuclei, and inconspicuous nucleoli. The nu-
clei show nuclear crowding and molding. Geographic 
necrosis, crush artifact, Azzopardi effect, and frequent 
mitotic figures are usually evident(14). The microscopic 
features of hematoxylin and eosin staining (H&E) sec-
tions usually lead to diagnosis. Nevertheless, for further 
confirmation and ruling out major differential diagno-
ses including malignant lymphoma, poorly differenti-
ated urothelial carcinoma and rhabdomyosarcoma, IHC 
studies are usually performed.
For the first time in 1986, Ordonez and colleagues used 
IHC staining to detect the differentiation of neuroendo-
crine cells, constituting the origin of this type of cancer 
(15). SmccB exhibits both neuroendocrine and epithelial 
markers(6). A recent study has reported that CD56 may 
be among the most sensitive neuroendocrine markers, 
staining 71.4% of bladder SmCC cases, followed by 
synaptophysin and chromogranin(16). Neuron Specific 
Enolase (NSE) is positive in 25-100%, Chromogranin 
in 22-89%, and Synaptophysin in 67-76% of SmccB 
patients(14,17,18).
Several epithelial markers are also positive in this can-
cer. CK-7 and Epithelial Membrane Antigen (EMA) are 
positive in 60% and 80% of SmccB patients, respec-
tively(4,19). Tumors show a dot-like positivity for pan-
cytokeratin. Markers of neuroendocrine differentiation 
including Synaptophysin, Chromogranin, CD 56, NSE 
are usually positive in tumoral cells. However, CD 
45, Myogenin, and Desmin are negative(20). IHC panel 
should include CD56, CD45, Synaptophysin, CAM-22, 
and CK8/18(6).
In our experience, the IHC staining was performed with 
the aim of demonstrating the neuroendocrine differen-
tiation, presence of epithelial elements, and excluding 
other malignancies. For each patient, between 6 and 16 
markers and on average 8 markers were used.
The use of IHC staining to diagnose SmccB routinely 
is still controversial. Some pathologists only use IHC 
staining for supplementation of morphological recog-
nition, and believe that neuroendocrine markers are 
not required to make diagnosis(21). On the other hand, a 
IHC marker Positive Negative Not performed
CD56 9 (69%) 1 (8%) 3 (23%)
NSE 5 (38%) 1 (8%) 7 (54%)
Synaptophysin 7 (54%) 3 (23%0 3 (23%)
Chromogranin 4 (31%) 6 (46%) 3 (23%)
Table 4. Positivity of markers of neuroendocrine differentiation 
in patients
Abbreviations: IHC, Immunohistochemical; NSE, neuron specif-
ic enolase
Figure 4.  Kaplan-Meier curves to compare survival across sur-
vival based on pathological or clinical stage (narrow spaced dotted 
line indicates stage T2, wide dotted line indicates stage T4 and 
solid line indicates stage T3)
Figure 5.  Kaplan-Meier curves to compare survival across sur-
vival based on treatment strategy (solid line indicates chemother-
apy plus surgery, dashed line indicates only chemotherapy, wide 
spaced dotted line indicates only surgery, and narrow spaced dot-
ted line indicates no treatment)
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significant number of uropathologists also perform IHC 
staining to help and support SmccB diagnosis(13).
Another opinion emphasizes the use of IHC staining 
for diagnostic confirmation ruling out some malignan-
cies including lymphoma(6). In our experience, only 
IHC stained samples were correctly diagnosed at ini-
tial pathology examination of TURBT samples despite 
evaluation of pathology samples by an experiences 
uro-pathologist with more than 20 years of experience. 
Therefore, we strongly recommend the use of IHC for 
diagnosis of SmccB in TURBT samples.
The rarity of this cancer has created many difficulties in 
the design of appropriate prospective clinical trials with 
the aim of finding better treatment modalities(22,23). For 
this reason, treatment modalities are not standard, and 
current therapeutic options are mainly based on limited 
retrospective small case series. The treatment requires a 
multiple and different clinical approach. The physician 
should be aware of the clinical stage of cancer in the 
initial presentation and the patient’s status , as it may 
impose some restrictions on the use of certain therapies 
(8,22). In this regard, in our experience, renal function 
impairment significantly affected proper chemotherapy 
and radical surgery in some patients.
In a study, Kouba et al. compared the results of 23 ar-
ticles in the treatment of bladder small cell carcinoma 
(7). Of these, only one paper was prospective and the 
rest were retrospective. The results of this study indicat-
ed that the highest average survival rate was observed 
in patients who underwent radical cystectomy with 
chemotherapy and/or radiotherapy, while the minimum 
survival was observed in the bladder sparing only with-
out referring to the pathologic stage of the cancer.
The primary manifestation in more than one-third of 
patients is advanced disease and distant metastases, 
and the average survival rate for all patients is 10-21 
months. On the other hand, distant metastases, the most 
common cause of death in these patients, occur in 70-
80% of patients who do not respond to the treatment 
(24,25). Therefore, chemotherapy plays an important role 
in the treatment of SmccB, which is indeed the main-
stay of SmccB treatment(26).
Also, our patients’ data revealed that the therapeutic 
results in the chemotherapy received group were far 
better than those who did not receive chemotherapy for 
any reason. Out of 8 chemotherapy receiving patients, 
six (75%) patients with an average survival of 46.377 
months (range: 9.4 – 60.3) were alive at the last fol-
low-up. 
Interestingly, the percentages of patients undergoing 
radical surgery in stage T2, T3, and T4 were 0%,75%, 
and 60% respectively (Table 3). On the other hand, 
75% of patients in stage T2, 50% in stage T3, and 60% 
in stage 4 received chemotherapy. Two patients with a 
pathological stage of T4a N+ with a mean 55.4-month 
follow up were alive at the last follow-up.
 For local cancer control, we only used radical surgery, 
and none of our patients was managed with radiother-
apy. The difference in survival in patients undergoing 
surgery with those who were not operated is not sig-
nificant.
Our study indicated that the average survival rate in 
patients undergoing radical surgery plus chemotherapy 
(47.7 months) was slightly superior however not statis-
tically significant to patients who received only chemo-
therapy (42.4 months). 
According to these findings, we believe that the most 
effective treatment option for SmccB given the clinical 
or pathological stage is chemotherapy and addition of 
radical surgery may offer a better survival.
One of the clinical findings that attracted our attention 
was the relatively high prevalence of impaired renal 
function secondary to ureteral obstruction, of which six 
patients had serum creatinine levels above 1.5mg/dL. 
Average serum Cr levels in this group was 3.06 mg/
dL (1.6-4.7). This finding, together with the high prev-
Figure 6. A) Microscopic examination of tumor shows patternless growth of discohesive small neoplastic cells with scant cytoplasms and 
hyperchromatic nuclei. The picture shows invasion of tumoral cells into muscularis propria; B) Immunohistochemical staining reveals 
diffuse positive immunoreactions for CD 56 and NSE in tumoral cells in one case (x20). C) Immunohistochemical staining reveals diffuse 
positive immunoreactions for CD 56 and NSE in tumoral cells in one case (x20).
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alence of hydronephrosis, is associated with advanced 
disease at presentation and is consistent with the patho-
logic stage of the patients.
In our patients, as mentioned above, the average size of 
the bladder mass in the first imaging was 7.54 cm. Hy-
dronephrosis and impaired renal function were seen in 
more than half of the patients in the first manifestation 
of the disease. In addition, the mean total creatinine in 
all 13 patients also lied within the range of renal fail-
ure. This issue, in addition to the advanced stage of the 
disease, will be a barrier to optimal radiological diag-
nosis with contrast agents and effective chemotherapy 
which as we discussed earlier constitutes the mainstay 
of treatment. 
The limitations of our study for clinical judgment are 
small number of cases, retrospective nature, different 
disease stage, different treatment modalities, and small 
cases in each stage.
CONSLUSIONS
Definitive diagnosis of SmccB requires the help Of IHC 
in most cases. Chemotherapy constitutes the mainstay 
of treatment with additional surgery offering a slightly 
better survival. 
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